Skeletal Scintigraphy in Assesing the Response of Prostate Cancer Metastases to Androgen Deprivation Therapy

Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone agonists is the basis for drug treatment in patients with metastatic prostate cancer (PC). An accurate assessment of the response of the tumor and its metastases is of primary importance for making a clinical decision regarding the continuation of treatment, changing the line of drugs or the nature of therapy. The presented clinical case illustrates the possibilities of ^99mTc-pyrophosphate skeletal scintigraphy for monitoring the response of PC bone metastases to ADT. The efficiency of hormone therapy with Triptorelin has been confirmed by positive changes in the visual and quantitative scintigraphic signs that manifest the metabolic activity of bone tissue in the area of a metastatic lesion. This was manifested by a marked decrease in the intensity of ^99mTc-pyrophosphate accumulation in the foci of bone pathology, by a reduction in the number of visualized hot foci, and by a gradual normalization of the scintigraphic pattern. This variant of the metabolic response of bone metastases to ADT correlated with the positive changes in laboratory parameters, as well as with the signs of reversal of the tumor and its metastases, as evidenced by magnetic resonance imaging.

1. Кaprin АD, Starinskiy VV, Petrova GV (Eds) Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow; 2019: 250 p. (in Russian).

2. Кaprin АD, Starinskiy VV, Shahsadova AO. State of onсological care in Russia in 2019. Moscow; 2019: 239 p. (in Russian).

3. Gritskevich AА, Mishugin SV, Teplov АА, Rusakov IG. Stable castration level of testosterone in androgen-deprivation therapy as a predictor of optimal clinical control in patients with prostate cancer. Malignant Tumours. 2015; 1: 42–8 (in Russian). https://doi.org/10.18027/2224-5057-2015-1-42-48.

4. Bukharkin BV. Modern drug-based hormonal therapy for primary detected disseminated prostate cancer. Russian Medical Journal. 2003; 11: 688 (in Russian).

5. Levenson RM, Sauerbrunn BJ, Bates HR, et al. Comparative value of bone scintigraphy and radiography in monitoring in systemically treated prostatic carcinoma. Radiology. 1983; 146(2): 513–8. https://doi.org/10.1148/radiology.146.2.6294738.

6. Currie GM, Haase M, Hashmi R, Kiat H. Hormone therape in prostate cancer. J Nucl Med Technol. 2013; 41(1): 49–51. https://doi.org/10.2967/jnmt.112.118034.References

7. Wyngaert TV, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016; 43(9): 1723–38. https://doi.org/10.1007/s00259-016-3415-4.

8. Ryzhkov AD, Shiryaev SV, Odzharova AA, et al. 99M-TC-labelled phosphonate metastases bone scintigraphy. Medical Radiology and Radiation Safety. 2007; 52(4): 62–8 (in Russian).

9. Chao HS, Chang CP, Chiu CH, et al. Bone scan flare phenomen in non-small-cell lung cancer patients with gefitinib. Clin Nucl Med. 2009; 34(6): 346–9. https://doi.org/10.1097/RLU.0b013e3181a344df.

10. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22(14): 2942–53. https://doi.org/10.1200/JCO.2004.08.181.

11. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010; 1: 80–92. https://doi.org/10.7150/jca.1.80.

12. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50(Suppl 1): 122–50S. https://doi.org/10.2967/jnumed.108.057307.